Core Insights - Bruker reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.65 per share, and down from $0.76 per share a year ago, representing an earnings surprise of -9.23% [1] - The company posted revenues of $977.2 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.12%, but down from $979.6 million year-over-year [2] - Bruker shares have declined approximately 9.9% since the beginning of the year, contrasting with the S&P 500's gain of 1.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.37 on revenues of $785.22 million, and for the current fiscal year, it is $2.11 on revenues of $3.45 billion [7] - The estimate revisions trend for Bruker was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Instruments - Scientific industry, to which Bruker belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

BRUKER CORPORATION (NASDAQ: BRKR) Q4 2025 Earnings Presentation February 12, 2026 Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the S ...

Exhibit 99.1 Bruker Reports Fourth Quarter and Full Year 2025 Financial Results BILLERICA, Massachusetts – February 12, 2026 – Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's President and CEO, commented: "At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expect ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Bruker (BRKR) due to lower revenues, with a focus on how actual results will compare to estimates impacting stock price [1] Earnings Expectations - Bruker is expected to report quarterly earnings of $0.65 per share, reflecting a year-over-year decrease of 14.5% [3] - Revenue projections stand at $966.4 million, which is a decline of 1.4% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 9.84% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Bruker matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [9][10] - Bruker currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12] Historical Performance - In the last reported quarter, Bruker exceeded expectations by posting earnings of $0.45 per share against an expected $0.33, resulting in a surprise of +36.36% [13] - Over the past four quarters, Bruker has beaten consensus EPS estimates three times [14] Conclusion - While Bruker may not appear to be a strong candidate for an earnings beat, investors should consider other factors before making investment decisions [17]

Market Overview - The proteomics market was valued at USD 29.92 billion in 2025 and is projected to grow to USD 58.66 billion by 2031, with a CAGR of 11.87% from 2026 to 2031, driven by precision medicine, chronic diseases, and demand for advanced analytical tools [1] - The role of proteomic analysis is expanding in drug discovery, biomarker identification, and disease pathway analysis, enhancing target validation and supporting targeted therapies [2] Regional Analysis - North America leads the proteomics market due to strong investment in biomedical research, advanced laboratory infrastructure, and the presence of major pharmaceutical and biotechnology companies [3] - Europe holds a significant market share, supported by active research programs and a focus on personalized medicine [4] - Asia-Pacific is emerging as a high-growth region, driven by expanding research capabilities and increasing government funding for life sciences [4] Market Trends - There is a growing adoption of proteomics in drug discovery to identify disease biomarkers and improve understanding of therapeutic targets [5] - The integration of proteomics with genomics is enhancing its role in precision medicine, enabling personalized approaches to disease diagnosis and treatment [6] Industry Segmentation - The proteomics market is segmented by components, technologies, and applications, including drug discovery and development [7] - Key technologies include mass spectrometry, chromatography, and next-generation sequencing [8] Competitive Landscape - The proteomics industry consists of established life science technology providers and specialized proteomics solution companies, focusing on expanding analytical capabilities and forming strategic collaborations [9]

Bruker Corporation (NASDAQ:BRKR) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January 26, Guggenheim analyst Subbu Nambi reiterated her Buy rating on Bruker Corporation (NASDAQ:BRKR). She revised her price target from $53 to $58, which leads to an upside potential of almost 25%. Copyright: dolgachov / 123RF Stock Photo Nambi’s target price adjustment is part of Guggenheim’s revisions to its forecasts and targets for many of the stocks within the Diagnostics and ...

Core Insights - The core viewpoint of the article highlights the significant growth and concentration of the atomic force microscope (AFM) market in China, with a total procurement of 137 units valued at over 278 million yuan in 2025, predominantly driven by international brands [1][2]. Market Overview - In 2025, a total of 137 atomic force microscopes were procured in China, with a total expenditure exceeding 278 million yuan, indicating a strong investment in research equipment in fields like nanotechnology, materials science, and life sciences [2]. - The market is characterized by high concentration, with three major international brands—Bruker, Oxford, and Park—dominating the landscape, collectively accounting for approximately 64% of the procurement quantity and over 70% of the monetary share [4]. Brand Competition - Bruker leads the market with 38 units procured, holding a 29% share in quantity and 38% in monetary terms, primarily due to its Dimension ICON and NanoWizard series [4]. - Oxford Instruments follows with 24 units, leveraging models like Cypher S and MFP-3D to maintain competitiveness in niche areas [4]. - Domestic brands, such as Benyuan Nano, are emerging in specific sectors, with Benyuan Nano securing 5 units, while others like Guoyi Quantum and ZhiZhen Precision have also made minor contributions [4]. Import vs. Domestic Equipment - Imported equipment dominates both in quantity and monetary value, with 101 units (73.7%) and a total value of 227 million yuan (81.6%), compared to 32 units (23.4%) and 4.4 million yuan (15.7%) for domestic equipment [9]. Seasonal Procurement Trends - The procurement activity exhibits strong seasonal characteristics, with the fourth quarter (October to December) being the peak period, accounting for 46.7% of total purchases, reflecting the alignment with fiscal budget execution [11][12]. Regional Distribution - The procurement distribution shows a clear regional concentration, correlating with the scientific and educational strength of the areas. The top regions include Shanghai and Zhejiang (14 units each), followed by Guangdong (12 units) and Beijing (11 units), collectively accounting for 44.53% of total procurement [15]. Procurement Entities - Leading buyers include top-tier universities and research institutions, such as Zhejiang University and Tsinghua University, which are significant contributors to high-end and high-value model purchases [16]. Technological Trends - Key technological trends in the market include high-speed and video-level imaging for observing dynamic biological and chemical processes, as well as specialized and customized systems for specific fields like semiconductors and energy materials [17][18]. Summary and Outlook - The 2025 Chinese atomic force microscope market is characterized by distinct brand hierarchies, concentrated geographical demand, and significant differences in procurement needs. The demand for high-end microscopy tools is expected to continue growing, particularly in regions with strong research capabilities [19]. - Future considerations include how international brands will strengthen their positions in high-value markets and whether domestic brands can leverage localized services to penetrate mainstream research markets [20].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - The Department of Energy (DOE) is implementing the Fusion Science and Technology Roadmap (FS&T Roadmap) to transition fusion energy from laboratory research to commercial viability by the mid-2030s [1][5] - The roadmap outlines a phased approach: near-term focus on digitalization and infrastructure, mid-term on prototype integration, and long-term on grid delivery and scale-up [2][3] Near-Term Actions - Emphasis on digitalization and infrastructure preparation to support fusion technology development [1] - Launch of the AI-Fusion Digital Convergence Platform to enhance materials discovery and plasma behavior prediction [4] Mid-Term Actions - Integration of prototypes to test and refine fusion technologies [2] - Construction of small-to-medium test facilities and design completion for large-scale "First-of-a-Kind" (FOAK) facilities [4] Long-Term Goals - Delivery of power to the grid from the first fleet of pilot plants [4] - Expansion of public infrastructure to support a global fusion market, aiming to lower the levelized cost of energy [4] Core Technical Challenges - The DOE has identified six core technical challenge areas to address gaps in fusion technology [3] - Key areas include structural materials, plasma-facing components, confinement systems, fuel cycle and tritium processing, blankets, and plant engineering [4][10] Material Development - Development of Reduced Activation Ferritic Martensitic (RAFM) steels and vanadium alloys to withstand neutron bombardment and minimize radioactive waste [11] - Focus on tungsten for plasma-facing components to handle extreme heat without contamination [12] Fusion Confinement Methods - The FS&T Roadmap pursues both Magnetic Confinement Fusion and Inertial Confinement Fusion [14] - Magnetic confinement utilizes High-Temperature Superconducting (HTS) magnets to stabilize plasma, with Tokamaks and Stellarators as primary architectures [15][18] Inertial Confinement Fusion - This method employs high-energy lasers to compress fuel pellets, igniting plasma through micro-explosions [19] - Companies involved in producing optical components and high-power diodes are critical to this approach [20] Tritium Breeding and Fuel Cycle - The DOE aims for a closed-loop fuel cycle to breed tritium using lithium-containing blankets, ensuring domestic supply and minimizing reliance on international sources [21] - Companies like Oklo and BWXT are involved in tritium production and breeding technologies [24][25] Blanket Technology - The blanket in fusion reactors is essential for energy conversion, tritium breeding, and radiation shielding [29] - The DOE is aligning advanced fission research and development with fusion technology to create a unified supply chain [30] Plant Engineering and Systems Integration - Focus on the Balance of Plant (BOP) to ensure reliability and efficiency in converting fusion energy to electricity [31] - Innovations such as Supercritical CO2 turbines are being prioritized for their efficiency and smaller footprint [32]